Poseida Therapeutics, Inc. (NASDAQ:PSTX) CEO Sells $558,531.54 in Stock


Share on StockTwits

Poseida Therapeutics, Inc. (NASDAQ:PSTX) CEO Eric Ostertag sold 57,819 shares of the company’s stock in a transaction that occurred on Monday, April 5th. The shares were sold at an average price of $9.66, for a total value of $558,531.54. Following the sale, the chief executive officer now owns 542,985 shares in the company, valued at approximately $5,245,235.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Eric Ostertag also recently made the following trade(s):

  • On Thursday, April 1st, Eric Ostertag sold 57,181 shares of Poseida Therapeutics stock. The shares were sold at an average price of $9.55, for a total value of $546,078.55.
  • On Tuesday, February 16th, Eric Ostertag sold 133,149 shares of Poseida Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $1,331,490.00.
  • On Wednesday, February 10th, Eric Ostertag sold 12,389 shares of Poseida Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $123,890.00.
  • On Thursday, January 21st, Eric Ostertag sold 4,462 shares of Poseida Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $44,620.00.

NASDAQ:PSTX opened at $8.98 on Thursday. The firm has a market capitalization of $557.73 million and a PE ratio of -1.31. The stock has a 50 day moving average of $10.21 and a 200-day moving average of $10.08. Poseida Therapeutics, Inc. has a 52 week low of $7.63 and a 52 week high of $17.62.

Poseida Therapeutics (NASDAQ:PSTX) last posted its earnings results on Thursday, March 11th. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.11. On average, sell-side analysts forecast that Poseida Therapeutics, Inc. will post -3 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. Pentwater Capital Management LP bought a new position in Poseida Therapeutics in the 3rd quarter worth approximately $43,281,000. BlackRock Inc. grew its holdings in Poseida Therapeutics by 62.1% in the 4th quarter. BlackRock Inc. now owns 1,548,443 shares of the company’s stock worth $16,987,000 after buying an additional 593,188 shares in the last quarter. Boxer Capital LLC bought a new position in Poseida Therapeutics in the 3rd quarter worth approximately $11,097,000. Perceptive Advisors LLC bought a new position in Poseida Therapeutics in the 3rd quarter worth approximately $6,987,000. Finally, UBS Asset Management Americas Inc. bought a new position in Poseida Therapeutics in the 3rd quarter worth approximately $2,458,000. 41.09% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research lowered Poseida Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 17th.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC.

Read More: Most Volatile Stocks

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.